Role of CDK5 in neuroprotection from serum deprivation by μ-opioid receptor agonist

Ying Wang, Wei Yan Xie, Yi He, Min Wang, Yan Rui Yang, Ying Zhang, Dongmin Yin, Kelly L. Jordan-Sciutto, Ji Sheng Han, Yun Wang

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Cyclin-dependent kinase 5 (CDK5), a unique member of the CDK family of cyclin-dependent kinases, is predominantly expressed in postmitotic neurons with proposed roles in both cell survival and programmed cell death. To understand how CDK5 participates in such disparate cellular outcomes, we investigated whether activation of CDK5 could mediate neuroprotection from serum deprivation by μ-opioid receptor agonist in differentiated SH-SY5Y cells and primary hippocampal neurons. We found that CDK5 kinase activity decreased following serum deprivation in differentiated SH-SY5Y cells coincident with increased cell loss and activation of caspases cascade activation, which was reversed by opioid antagonist. Overexpression of CDK5 in serum-free medium reversed activation of caspase cascade and augmented DAMGO neuroprotection. Blocking CDK5 activity by pharmacologic inhibitor, roscovitine or overexpression of dominant negative CDK5 augmented activation of cell death markers and diminished μ-opioid receptor agonist protection. Reduction in CDK5 activity corresponded to reduction in protein levels of CDK5 activator p35 during serum deprivation which was also reversed by μ-opioid receptor agonist. Phosphorylation of STAT3 at Serine 727 by CDK5 decreased during serum deprivation, and partly recovered by μ-opioid agonist. PI3K signaling pathway was not required for CDK5-mediated μ-opioid neuroprotection against serum deprivation. These findings indicate that neuroprotection by μ-opioid receptor agonist against serum deprivation is mediated by activation of CDK5 through up-regulation of p35 and phosphorylation of STAT3 by CDK5 may contribute to the neuroprotection.

Original languageEnglish (US)
Pages (from-to)313-323
Number of pages11
JournalExperimental Neurology
Volume202
Issue number2
DOIs
StatePublished - Dec 1 2006

Fingerprint

Cyclin-Dependent Kinase 5
Opioid Receptors
Serum
Caspases
Neuroprotection
Opioid Analgesics
Cell Death
Phosphorylation
Ala(2)-MePhe(4)-Gly(5)-enkephalin
Neurons
Narcotic Antagonists
Cyclin-Dependent Kinases
Serum-Free Culture Media
Phosphatidylinositol 3-Kinases

Keywords

  • Cyclin-dependent kinase 5
  • Neuronal survival
  • Neuroprotection
  • PI3K
  • Serum deprivation
  • p-STAT3
  • p35
  • μ-Opioid agonist

ASJC Scopus subject areas

  • Neurology
  • Developmental Neuroscience

Cite this

Wang, Y., Xie, W. Y., He, Y., Wang, M., Yang, Y. R., Zhang, Y., ... Wang, Y. (2006). Role of CDK5 in neuroprotection from serum deprivation by μ-opioid receptor agonist. Experimental Neurology, 202(2), 313-323. https://doi.org/10.1016/j.expneurol.2006.06.005

Role of CDK5 in neuroprotection from serum deprivation by μ-opioid receptor agonist. / Wang, Ying; Xie, Wei Yan; He, Yi; Wang, Min; Yang, Yan Rui; Zhang, Ying; Yin, Dongmin; Jordan-Sciutto, Kelly L.; Han, Ji Sheng; Wang, Yun.

In: Experimental Neurology, Vol. 202, No. 2, 01.12.2006, p. 313-323.

Research output: Contribution to journalArticle

Wang, Y, Xie, WY, He, Y, Wang, M, Yang, YR, Zhang, Y, Yin, D, Jordan-Sciutto, KL, Han, JS & Wang, Y 2006, 'Role of CDK5 in neuroprotection from serum deprivation by μ-opioid receptor agonist', Experimental Neurology, vol. 202, no. 2, pp. 313-323. https://doi.org/10.1016/j.expneurol.2006.06.005
Wang, Ying ; Xie, Wei Yan ; He, Yi ; Wang, Min ; Yang, Yan Rui ; Zhang, Ying ; Yin, Dongmin ; Jordan-Sciutto, Kelly L. ; Han, Ji Sheng ; Wang, Yun. / Role of CDK5 in neuroprotection from serum deprivation by μ-opioid receptor agonist. In: Experimental Neurology. 2006 ; Vol. 202, No. 2. pp. 313-323.
@article{1f4363258a0941d0950c84963221ac45,
title = "Role of CDK5 in neuroprotection from serum deprivation by μ-opioid receptor agonist",
abstract = "Cyclin-dependent kinase 5 (CDK5), a unique member of the CDK family of cyclin-dependent kinases, is predominantly expressed in postmitotic neurons with proposed roles in both cell survival and programmed cell death. To understand how CDK5 participates in such disparate cellular outcomes, we investigated whether activation of CDK5 could mediate neuroprotection from serum deprivation by μ-opioid receptor agonist in differentiated SH-SY5Y cells and primary hippocampal neurons. We found that CDK5 kinase activity decreased following serum deprivation in differentiated SH-SY5Y cells coincident with increased cell loss and activation of caspases cascade activation, which was reversed by opioid antagonist. Overexpression of CDK5 in serum-free medium reversed activation of caspase cascade and augmented DAMGO neuroprotection. Blocking CDK5 activity by pharmacologic inhibitor, roscovitine or overexpression of dominant negative CDK5 augmented activation of cell death markers and diminished μ-opioid receptor agonist protection. Reduction in CDK5 activity corresponded to reduction in protein levels of CDK5 activator p35 during serum deprivation which was also reversed by μ-opioid receptor agonist. Phosphorylation of STAT3 at Serine 727 by CDK5 decreased during serum deprivation, and partly recovered by μ-opioid agonist. PI3K signaling pathway was not required for CDK5-mediated μ-opioid neuroprotection against serum deprivation. These findings indicate that neuroprotection by μ-opioid receptor agonist against serum deprivation is mediated by activation of CDK5 through up-regulation of p35 and phosphorylation of STAT3 by CDK5 may contribute to the neuroprotection.",
keywords = "Cyclin-dependent kinase 5, Neuronal survival, Neuroprotection, PI3K, Serum deprivation, p-STAT3, p35, μ-Opioid agonist",
author = "Ying Wang and Xie, {Wei Yan} and Yi He and Min Wang and Yang, {Yan Rui} and Ying Zhang and Dongmin Yin and Jordan-Sciutto, {Kelly L.} and Han, {Ji Sheng} and Yun Wang",
year = "2006",
month = "12",
day = "1",
doi = "10.1016/j.expneurol.2006.06.005",
language = "English (US)",
volume = "202",
pages = "313--323",
journal = "Experimental Neurology",
issn = "0014-4886",
publisher = "Academic Press Inc.",
number = "2",

}

TY - JOUR

T1 - Role of CDK5 in neuroprotection from serum deprivation by μ-opioid receptor agonist

AU - Wang, Ying

AU - Xie, Wei Yan

AU - He, Yi

AU - Wang, Min

AU - Yang, Yan Rui

AU - Zhang, Ying

AU - Yin, Dongmin

AU - Jordan-Sciutto, Kelly L.

AU - Han, Ji Sheng

AU - Wang, Yun

PY - 2006/12/1

Y1 - 2006/12/1

N2 - Cyclin-dependent kinase 5 (CDK5), a unique member of the CDK family of cyclin-dependent kinases, is predominantly expressed in postmitotic neurons with proposed roles in both cell survival and programmed cell death. To understand how CDK5 participates in such disparate cellular outcomes, we investigated whether activation of CDK5 could mediate neuroprotection from serum deprivation by μ-opioid receptor agonist in differentiated SH-SY5Y cells and primary hippocampal neurons. We found that CDK5 kinase activity decreased following serum deprivation in differentiated SH-SY5Y cells coincident with increased cell loss and activation of caspases cascade activation, which was reversed by opioid antagonist. Overexpression of CDK5 in serum-free medium reversed activation of caspase cascade and augmented DAMGO neuroprotection. Blocking CDK5 activity by pharmacologic inhibitor, roscovitine or overexpression of dominant negative CDK5 augmented activation of cell death markers and diminished μ-opioid receptor agonist protection. Reduction in CDK5 activity corresponded to reduction in protein levels of CDK5 activator p35 during serum deprivation which was also reversed by μ-opioid receptor agonist. Phosphorylation of STAT3 at Serine 727 by CDK5 decreased during serum deprivation, and partly recovered by μ-opioid agonist. PI3K signaling pathway was not required for CDK5-mediated μ-opioid neuroprotection against serum deprivation. These findings indicate that neuroprotection by μ-opioid receptor agonist against serum deprivation is mediated by activation of CDK5 through up-regulation of p35 and phosphorylation of STAT3 by CDK5 may contribute to the neuroprotection.

AB - Cyclin-dependent kinase 5 (CDK5), a unique member of the CDK family of cyclin-dependent kinases, is predominantly expressed in postmitotic neurons with proposed roles in both cell survival and programmed cell death. To understand how CDK5 participates in such disparate cellular outcomes, we investigated whether activation of CDK5 could mediate neuroprotection from serum deprivation by μ-opioid receptor agonist in differentiated SH-SY5Y cells and primary hippocampal neurons. We found that CDK5 kinase activity decreased following serum deprivation in differentiated SH-SY5Y cells coincident with increased cell loss and activation of caspases cascade activation, which was reversed by opioid antagonist. Overexpression of CDK5 in serum-free medium reversed activation of caspase cascade and augmented DAMGO neuroprotection. Blocking CDK5 activity by pharmacologic inhibitor, roscovitine or overexpression of dominant negative CDK5 augmented activation of cell death markers and diminished μ-opioid receptor agonist protection. Reduction in CDK5 activity corresponded to reduction in protein levels of CDK5 activator p35 during serum deprivation which was also reversed by μ-opioid receptor agonist. Phosphorylation of STAT3 at Serine 727 by CDK5 decreased during serum deprivation, and partly recovered by μ-opioid agonist. PI3K signaling pathway was not required for CDK5-mediated μ-opioid neuroprotection against serum deprivation. These findings indicate that neuroprotection by μ-opioid receptor agonist against serum deprivation is mediated by activation of CDK5 through up-regulation of p35 and phosphorylation of STAT3 by CDK5 may contribute to the neuroprotection.

KW - Cyclin-dependent kinase 5

KW - Neuronal survival

KW - Neuroprotection

KW - PI3K

KW - Serum deprivation

KW - p-STAT3

KW - p35

KW - μ-Opioid agonist

UR - http://www.scopus.com/inward/record.url?scp=33750626424&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33750626424&partnerID=8YFLogxK

U2 - 10.1016/j.expneurol.2006.06.005

DO - 10.1016/j.expneurol.2006.06.005

M3 - Article

VL - 202

SP - 313

EP - 323

JO - Experimental Neurology

JF - Experimental Neurology

SN - 0014-4886

IS - 2

ER -